---
schema_version: "secwatch.filing_event.v1"
accession: "0001625101-22-000008"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2022-02-15T23:59:59+00:00"
generated_at: "2026-06-27T08:00:16.045495+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences appoints Kevin Danahy as Chief Commercial Officer, effective Feb 14

## Summary
- Kevin Danahy named CCO; receives $395,000 base salary, 50% target bonus.
- Granted 300,000 stock options at $6.41/share (Feb 14 closing price), 4-year vesting.
- Danahy has 20+ years in medtech; previously President at Solmetex, VP at Zimmer Biomet.
- Appointment is an inducement award under Nasdaq Rule 5635(c)(4).

## SEC filing metadata
- accession: 0001625101-22-000008
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2022-02-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000162510122000008/0001625101-22-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000162510122000008/plse-20220209x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001625101-22-000008
- JSON: https://secwatch.observer/filing/0001625101-22-000008.json
- Plain text: https://secwatch.observer/filing/0001625101-22-000008.txt

## Key facts
- Executive change
  Kevin Danahy was appointed as Chief Commercial Officer at PULSE BIOSCIENCES, INC..
  - Action: appointed
  - Role: Chief Commercial Officer
  source text: On February 15, 2022, Pulse Biosciences, Inc. announced the appointment of Kevin Danahy to the newly created role of Chief Commercial Officer, effective February 14, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625101/000162510122000008/0001625101-22-000008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.